Adverse Drug Reactions and Drug Delivery

webinar

Thu, 30 Nov 2023, 16:00 CET (Berlin)

Prof. Dr. Laleh Alisaraie, Memorial University of Newfoundland, Canada

Adverse Drug Reactions and Drug Delivery

Adverse drug reactions (ADRs) are not only a significant concern in public health but also one of the main challenges in drug discovery. This is especially true for anti-cancer drug development, which is slow and costly; ADRs can also be the cause of drug withdrawals from the market. The interactions of anti-cancer drugs at off-target sites in the body may result in a wide range of undesired effects that occur through complex biological mechanisms and may turn out severe enough so that they result in hospital admissions. A suitable drug delivery system cannot only improve the effectiveness of a drug but also serve to reduce its adverse reactions.

In this BioSolveIT Webinar, Laleh will discuss case studies, where the application of computational simulations has aided. This covers the analysis of a drug mechanism of action at potential off-target sites, or designing and evaluating specific drug delivery systems to mitigate the unwanted impact of chemotherapeutic agents.

Join us for an interesting twist on computational drug discovery methods and vivid discussions!

Current news

What's So Special About The 'Activity Spotter'? Detailed Insights Into SeeSAR's New Mode
April 29, 2026 10:22 CEST
SeeSAR’s Activity Spotter Mode is designed to dismantle the barrier of raw data and actionable SAR. It helps to answer the most relevant fields in hit-to-lead and lead optimization campaigns: 3D SAR and pharmacophore modeling. Which structural features in my molecule set are associated with activity? Which ones are linked...
Read on
Tool of the Month - FlexX
April 29, 2026 08:53 CEST
Spring is Molecular Docking Season The bread and butter of computational chemistry: predicting potential binding modes, which serves as a crucial foundation for SAR analysis and design decisions, is being made available to everyone this month with the proprietary docking tool FlexX. Validated by over 10,000 citations of its original...
Read on
The 95 Billion Update: Access the REAL Space
April 9, 2026 13:57 CEST
The latest update of Enamine’s REAL Space brings a new expansion, now featuring over 94.5 billion accessible, drug-like products, approaching the 100 billion mark. Built from 173 curated reaction protocols and 202,620 in-stock reagents and building blocks based on Enamine’s in-house knowledge, this version further enhances the world’s largest commercially...
Read on